[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid-induced-constipation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid-induced-constipation":56},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100585096","phase-4-real-world-study-of-oxycodonenaloxone-sustained-release-tablets-mimeixin-for-patients-with-severe-cancer-pain-100585096",false,"NCT06897917","Real World Study of Oxycodone\u002FNaloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain","Inclusion Criteria:\n\n* Age ≥ 18 years old, with a histological or pathological diagnosis of advanced cancer.\n* Be diagnosed with severe (NRS ≥ 7 points) cancer pain, requiring regular opioid therapy.\n* Diagnosed with OIC according to the Rome IV diagnostic criteria for OIC, with a BFI score ≥ 30.\n* Determined by the investigator to be eligible for treatment with oxycodone\u002Fnaloxone sustained-release tablets.\n* Estimated survival period of more than 3 months.\n* Voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with contraindications to oxycodone\u002Fnaloxone sustained-release tablets (including allergy to the active ingredients or any excipients of this product; severe respiratory depression accompanied by hypoxemia and\u002For hypercapnia; severe chronic obstructive pulmonary disease; pulmonary heart disease; severe bronchial asthma; paralytic ileus caused by non-opioid drugs; moderate to severe liver function impairment).\n* Patients with structural malformations of the gastrointestinal tract (such as intestinal obstruction, stenosis), other known gastrointestinal diseases\u002Fsymptoms (including cancer metastasis to the digestive tract), or gastrointestinal digestion and absorption disorders.\n* Patients with language communication barriers, cognitive impairments or mental illnesses, intracranial metastasis of tumors with consciousness disorders, or consciousness disorders caused by other reasons.\n* Other situations that the investigator judges as unsuitable for inclusion in the study.","ALL","18 Years",{"count":18,"type":19},203,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.",[25,26],"Opioid-Induced Constipation","Pain Cancer",[28,29,30],"opioid-induced constipation","severe cancer pain","Oxycodone\u002Fnaloxone sustained-release tablets","NOT_YET_RECRUITING","2025-03-26",{"date":34,"type":35},"2025-03-27","ACTUAL",{"date":37,"type":19},"2025-04",{"date":39,"type":19},"2025-12",{"name":41,"class":42},"Henan Cancer Hospital","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100341057","risk-of-major-adverse-cardiovascular-events-for-naldemedine--other-medications-for-opioid-induced-constipation-100341057","NCT03720613","Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation","Risk of Major Adverse Cardiovascular Events Among Users of Naldemedine Compared With Other Medications Used for Opioid Induced Constipation in Adult Patients With Chronic Non-Cancer Pain in a Healthcare Claims Database","Inclusion Criteria:\n\n* At least one dispensing of naldemedine or lubiprostone or naloxegol without prior use in the database of either medication (index date)\n* At least two dispensings of opioids within six months prior to and including the index date, with at least a combined 31 cumulative days supply\n* At least 18 years of age or older on the index date\n* At least six months of continuous health plan coverage that includes medical and pharmacy benefits prior to and including the index date\n\nExclusion Criteria:\n\n* Any acute MACE (non-fatal MI or non-fatal stroke) within six months before or on the index date\n* Any cancer treatment or cancer pain diagnosis within six months before or on the index date\n* Prior use of methylnaltrexone, alvimopan or naloxegol within six months before or on the index date",{"count":52,"type":19},34532,"OBSERVATIONAL","The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications.",[56],"Opioid-induced Constipation",[58,59,60,61,62],"naloxegol","major adverse cardiovascular event (MACE)","opioid induced constipation (OIC)","lubiprostone","naldemedine","RECRUITING","2025-02-10",{"date":66,"type":35},"2025-02-12",{"date":68,"type":35},"2019-01-04",{"date":70,"type":19},"2030-11-01",{"name":72,"class":73},"BioDelivery Sciences International","INDUSTRY"]